Hippo-YAP Pathway and Related miRNAs in Preterm Birth (NCT07695467) | Clinical Trial Compass
CompletedNot Applicable
Hippo-YAP Pathway and Related miRNAs in Preterm Birth
Turkey (Türkiye)44 participantsStarted 2021-06-01
Plain-language summary
This completed observational study evaluated the expression of Hippo-YAP pathway-related genes and proteins and selected microRNAs in maternal blood, placental tissue, and myometrial tissue obtained from women who underwent cesarean delivery at term or preterm gestational ages.
The study compared women with spontaneous preterm delivery and women with term delivery. Maternal blood, placental tissue, and myometrial tissue samples were analyzed using molecular, biochemical, and immunohistochemical methods to explore whether Hippo-YAP pathway activity and related miRNA expression patterns may be associated with the pathophysiology of preterm birth.
Who can participate
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
\- cInclusion Criteria:
* Pregnant women aged 18 years or older
* Singleton pregnancy
* Women who underwent cesarean delivery
* For the preterm delivery group: spontaneous preterm labor and delivery between 24 and 34 weeks of gestation
* For the term delivery group: cesarean delivery at term gestational age without active labor
* Written informed consent for participation and collection of maternal blood, placental tissue, and myometrial tissue samples
Exclusion Criteria:
* Multiple pregnancy
* Major fetal anomaly
* Clinical evidence of chorioamnionitis
* Hypertensive disorders of pregnancy
* Diabetes mellitus or gestational diabetes mellitus
* Autoimmune disease
* Chronic inflammatory disease
* Maternal systemic infection
* Placental abruption
* Premature rupture of membranes, if excluded in the original protocol
* Use of medications or presence of maternal conditions that could significantly affect inflammatory, molecular, or placental biomarker expression
* Refusal to provide informed consent
Exclusion Criteria:
\-
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Expression levels of Hippo-YAP pathway-related genes, proteins, and selected microRNAs